SpectraCure (SPEC) Q2 2026 earnings summary

Executive summary

• Advanced clinical studies for Q-PRO® system in recurrent and primary localized prostate cancer, with phase 2 of the recurrence study nearing completion and positive safety and efficacy data observed.

• Strengthened recruitment base with leading clinics in Europe and North America, expanding to additional sites in Germany pending regulatory approval.

• Completed a rights issue post-period, raising approximately 25.7 MSEK before costs, supporting continued clinical and regulatory activities.

Financial highlights

• Q2 2026 net loss after tax: -6,828 TSEK (Q2 2025: -7,202 TSEK); H1 2026 net loss: -12,967 TSEK (H1 2025: -13,517 TSEK).

• Earnings per share for Q2: -0.01 SEK (Q2 2025: -0.03 SEK); H1: -0.02 SEK (H1 2025: -0.06 SEK).

• Operating cash flow for Q2: -4,815 TSEK (Q2 2025: 4,172 TSEK); H1: -9,593 TSEK (H1 2025: -1,475 TSEK).

• Equity at June 30, 2026: 93,576 TSEK (June 30, 2025: 134,884 TSEK); cash and equivalents: 7,633 TSEK (9,250 TSEK).

• Solid equity ratio of 83% (78% in prior year period).

Outlook and guidance

• Focus remains on completing phase 2 of the recurrence study by spring, with preparations for phase 3 underway.

• The recent capital raise is expected to fund operations into Q1 2027; further financing may be needed depending on clinical progress and option exercise.